Is Brookfield Real Assets Income (RA) a Buy, Sell, or Hold?
NYSE : RA
Brookfield Real Assets Income
$12.785 USD
$0.03 (0.27%)
- Volume
- 149.85K
- Average Volume
- 158.92K
- Market Capitalization
- $706.43M
- P/E Ratio
- 11.42
- Dividend Yield
- 11.07%
- Price Target
- Year High
- $13.59
- Year Low
- $12.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $1.26
- Current Ratio
- $0.05
Company Overview
NYSE
Gaal Surugeon
Asset Management
Financial Services
RA
N/A
US
USD
212 549 8400
112830104
0001655099
Liquidity Metrics
0.33
0.05
0.05
0.01
1.26
Sales & Valuation
$77.57M
9.11
0.89
15.15
0.84
Profitability
$1.12
$61.88M
79.77%
79.77%
7.73%
5.83%
P/E Metrics
11.42
-2.67
-2.67
Analyst Price Target & Rating
3/5
4 Analysts
%
Financial Health Scores
1.71
6/9
-$245.96M
$1.06B
$265.97M
$151.36M
Key Metrics (TTM)
$962.81M
12.41
12.84
0.05
7.73%
7.05%
8.78%
6.62%
$19.04
-64 days
Company Executives
| Name | Title |
|---|---|
| Samuel Matthias Diedrich | Portfolio Manager |
Poll Results
No votes yet today — be the first to share your view!
About Brookfield Real Assets Income (NYSE:RA) Stock
Brookfield Real Assets Income Fund Inc. is a closed ended fixed income mutual fund launched and managed by Brookfield Investment Management Inc. The fund is co-managed by Schroder Investment Management North America Inc. It invests in fixed income markets of the United States. The fund primarily invests in securities and other instruments of companies, which includes real estate securities, infrastructure securities, and natural resources securities. Brookfield Real Assets Income Fund Inc. was formed on December 2, 2016 and is domiciled in the United States. ...
LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board of Directors
2026-07-27 10:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist program through Phase 1b clinical trials in rheumatoid arthritis (RA) and atopic dermatitis (AD). Kazimi brings more than two decades of biotechnology leadership experience spanning company building, corporate strategy, financing, and drug development. As CEO of Nimbus Therapeutics, he has overseen.
RA: A Classic Fixed-Income CEF In 'Real Assets' Clothing
2026-07-27 04:10:23
Brookfield Real Assets Income Fund is a fixed income CEF, not a direct real assets holder, despite its name. RA primarily invests in corporate and securitized credit, with only 7.9% in equities and no direct commodity or real estate exposure. The fund's 10% distribution is supported by significant return of capital (~30%), with true cash flow yield closer to 7%.
Brookfield Real Assets Income Fund (NYSE:RA) Shares Cross Above 200 Day Moving Average – Here’s Why
2026-07-23 02:41:35
Brookfield Real Assets Income Fund Inc. (NYSE: RA - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $12.93 and traded as high as $12.97. Brookfield Real Assets Income Fund shares last traded at $12.9540, with a volume of 122,956 shares
2026-06-29 04:00:00
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Brookfield Real Assets Income Fund Inc. Declares Q3 2026 Distribution Schedule
2026-06-26 16:58:00
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund's monthly distributions for July, August and September 2026.
Brookfield Real Assets Income Fund Inc. Announces Portfolio Management Team Change
2026-06-08 13:19:00
NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (the “Fund”) (NYSE: RA) today announced upcoming portfolio management changes at Oaktree Fund Advisors, LLC (“Oaktree”), the sub-adviser responsible for managing the Fund's securitized credit allocation.
Organon to Present New Research on Access and Value at ISPOR 2026
2026-05-15 08:00:00
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data acros
Frequently Asked Questions
-
What is the current Brookfield Real Assets Income (RA) stock price?
-
Brookfield Real Assets Income(NYSE:RA) stock price is $12.785 in the last trading session. During the trading session, RA stock reached the peak price of $13.59 while $12.5 was the lowest point it dropped to. The percentage change in RA stock occurred in the recent session was 0.27% while the dollar amount for the price change in RA stock was $0.03.
-
RA's industry and sector of operation?
-
The NYSE listed RA is part of Asset Management industry that operates in the broader Financial Services sector.
-
Who are the executives of RA?
-
Samuel Matthias Diedrich | Portfolio Manager
|
|
|
| -
How many employees does RA have?
-
Number of RA employees currently stands at None. RA operates from Brookfield Place, New York, NY 10281-1023, US.
-
Link for RA official website?
-
Official Website of RA is: https://publicsecurities.brookfield.com/us-closed-end-funds/brookfield-real-assets-income-fund?id=192676
-
How do I contact RA?
-
RA could be contacted at phone #212 549 8400 and can also be accessed through its website. RA operates from Brookfield Place, New York, NY 10281-1023, US.
-
How many shares of RA are traded daily?
-
The average number of RA shares traded daily for last 3 months was 158.92K.
-
What is the market cap of RA currently?
-
The market value of RA currently stands at $706.43M with its latest stock price at $12.785